This trial is testing a new way to detect FAP-expressing cells in patients with pancreatic cancer. The new method uses a PET scan with [68Ga]FAPI-46.
1 Primary · 5 Secondary · Reporting Duration: Through study completion, 2 years
Experimental Treatment
60 Total Participants · 1 Treatment Group
Primary Treatment: [68Ga]FAPI-46 · No Placebo Group · Phase 2
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: